On July 9, 2018 Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop novel multi-specific antibodies for undisclosed oncology targets (Press release, TeneoBio, JUL 9, 2018, View Source [SID1234527703]). Under the terms of the agreement, Teneobio will generate product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. For resulting therapeutic candidates, Janssen would have exclusive global licensing rights to the antibodies for clinical development and commercialization. The deal was facilitated by Johnson & Johnson Innovation LLC through its California Innovation Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Teneobio Inc. will receive an upfront payment and is eligible to receive future research, development and commercial milestone payments per potential candidate. Teneobio would also receive royalties on world–wide net sales of each multi-specific product. Financial terms of the agreement were not disclosed.
Roland Buelow, CEO of Teneobio, added, "We are excited to collaborate with Janssen and its oncology scientists to develop the next generation of therapeutic multispecific antibodies. Our UniRat-derived modular human variable heavy-chain antibody domains (UniDabs) enable the assembly of robust, optimized, multispecifics for T-cell redirection, as antibody drug-conjugates, and as extracellular domains of CAR T-cells to target cancers. Through Teneobio’s state-of-the-art discovery platforms, we look to discover and advance differentiated biotherapeutics to the clinic. Janssen‘s deep oncology expertise complements our interests and goals to address unmet medical needs with novel breakthrough therapeutics."